RPS6KA1 (Ab-573) Antibody
Shipped with Ice Packs 
In Stock 
Description
Introduction to RPS6KA1 (Ab-573) Antibody
RPS6KA1 (Ab-573) Antibody is a polyclonal antibody developed against the p90 ribosomal S6 kinase (RSK1) protein. This antibody specifically recognizes the region surrounding the threonine 573 phosphorylation site, which plays a critical role in RSK1 activation and downstream signaling pathways . The antibody is produced in rabbits using a synthesized non-phosphopeptide derived from human p90 RSK with the sequence L-M-T(p)-P-C .
Target Protein Background
The target protein, RPS6KA1 (also known as p90 RSK1), is a serine/threonine protein kinase that functions downstream of the ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling pathway . This kinase mediates mitogenic and stress-induced activation of various transcription factors, including CREB1, ETV1/ER81, and NR4A1/NUR77 . In cellular contexts, RPS6KA1:
-
Regulates translation through RPS6 and EIF4B phosphorylation
-
Promotes cellular proliferation, survival, and differentiation
-
Modulates mTOR signaling pathways
Applications and Experimental Validations
RPS6KA1 (Ab-573) Antibody has been validated for multiple laboratory applications, providing researchers with a versatile tool for investigating p90 RSK expression and function.
Validated Applications
The antibody has been tested and validated for the following applications:
-
Western Blotting (WB): Recommended dilution range 1:500-1:3000
-
Immunohistochemistry (IHC): Recommended dilution range 1:50-1:100
Experimental Results and Validations
Several experimental validations demonstrate the antibody's performance and specificity:
Western Blot Analysis
The antibody has been successfully used in Western blot analyses:
-
Detection of endogenous levels of total p90 RSK protein in extracts from 293 cells
-
Analysis of extracts from 3T3 cells treated with PMA (125ng/ml, 30 minutes)
Immunohistochemistry Analysis
Immunohistochemical staining has been performed on:
-
The antibody effectively demonstrates the tissue distribution and cellular localization of p90 RSK
Comparative Analysis with Other RPS6KA1 Antibodies
The RPS6KA1 (Ab-573) Antibody represents one of several antibodies targeting different phosphorylation sites and regions of the p90 RSK protein. While this antibody specifically targets the threonine 573 region, other commercially available antibodies target different phosphorylation sites:
RPS6KA1 Antibody Comparison
-
RPS6KA1 (Ab-573): Targets threonine 573 phosphorylation site
-
RPS6KA1 (pThr359/pSer363): Recognizes dual phosphorylation at threonine 359 and serine 363
This diversity allows researchers to study different aspects of p90 RSK activation and signaling based on specific phosphorylation states.
Research Applications and Significance
The RPS6KA1 (Ab-573) Antibody serves as a valuable tool in multiple research contexts investigating cellular signaling pathways, particularly those involving the MAPK/ERK cascade.
Signaling Pathway Studies
This antibody facilitates investigation of:
-
ERK signaling pathway activation and downstream effects
-
Mitogenic and stress-induced cellular responses
-
Phosphorylation-dependent activation mechanisms of p90 RSK
-
Translation regulation through p90 RSK-mediated phosphorylation
Potential Biomedical Applications
Research utilizing this antibody contributes to understanding:
-
Cancer cell proliferation and survival mechanisms
-
Neuronal differentiation and plasticity
-
Insulin signaling and metabolic regulation
-
Stress response pathways in various cellular contexts
Product Specs
Form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Lead Time
Typically, we can ship products within 1-3 business days of receiving your order. Delivery times may vary depending on the purchase method or location. Please consult your local distributor for specific delivery times.
Synonyms
90 kDa ribosomal protein S6 kinase 1 antibody; dJ590P13.1 (ribosomal protein S6 kinase; 90kD; polypeptide 1 antibody; dJ590P13.1 antibody; EC 2.7.11.1 antibody; HU 1 antibody; HU1 antibody; KS6A1_HUMAN antibody; MAP kinase activated protein kinase 1a antibody; MAP kinase-activated protein kinase 1a antibody; MAPK-activated protein kinase 1a antibody; MAPKAP kinase 1a antibody; MAPKAPK-1a antibody; MAPKAPK1A antibody; MGC79981 antibody; Mitogen-activated protein kinase-activated protein kinase 1A antibody; OTTHUMP00000004113 antibody; p90 RSK1 antibody; p90-RSK 1 antibody; p90rsk antibody; p90RSK1 antibody; p90S6K antibody; pp90RSK1 antibody; Ribosomal protein S6 kinase 90kD 1 antibody; Ribosomal protein S6 kinase 90kD polypeptide 1 antibody; Ribosomal protein S6 kinase 90kDa polypeptide 1 antibody; Ribosomal protein S6 kinase alpha 1 antibody; Ribosomal protein S6 kinase alpha-1 antibody; Ribosomal protein S6 kinase polypeptide 1 antibody; Ribosomal S6 kinase 1 antibody; RPS6K1 alpha antibody; rps6ka antibody; Rps6ka1 antibody; RSK 1 antibody; RSK 1 p90 antibody; RSK antibody; RSK-1 antibody; RSK1 antibody; RSK1p90 antibody; S6K alpha 1 antibody; S6K-alpha-1 antibody
Target Names
Uniprot No.
Target Background
Function
RPS6KA1, also known as ribosomal protein S6 kinase alpha-1, is a serine/threonine-protein kinase that operates downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling. It plays a crucial role in mediating mitogenic and stress-induced activation of transcription factors CREB1, ETV1/ER81, and NR4A1/NUR77. RPS6KA1 regulates translation by phosphorylating RPS6 and EIF4B, ultimately influencing cellular proliferation, survival, and differentiation. Its influence extends to modulating mTOR signaling and repressing the pro-apoptotic functions of BAD and DAPK1. In fibroblasts, RPS6KA1 is essential for EGF-stimulated phosphorylation of CREB1, which subsequently leads to the transcriptional activation of several immediate-early genes. In response to mitogenic stimulation (EGF and PMA), RPS6KA1 phosphorylates and activates transcription factors NR4A1/NUR77 and ETV1/ER81, along with the cofactor CREBBP. Upon insulin-derived signals, RPS6KA1 indirectly influences the transcriptional regulation of several genes by phosphorylating GSK3B at 'Ser-9', thereby inhibiting its activity. RPS6KA1 phosphorylates RPS6 in response to serum or EGF through an mTOR-independent mechanism, promoting translation initiation by facilitating the assembly of the pre-initiation complex. Following insulin exposure, RPS6KA1 phosphorylates EIF4B, enhancing its affinity for the EIF3 complex and stimulating cap-dependent translation. RPS6KA1 participates in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', potently inhibiting TSC2's ability to suppress mTOR signaling. It also mediates the phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway. RPS6KA1 contributes to cell survival by phosphorylating pro-apoptotic proteins BAD and DAPK1, thereby suppressing their pro-apoptotic functions. It promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4). RPS6KA1 mediates the induction of hepatocyte proliferation by TGFA through phosphorylation of CEBPB. It is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, promoting its association with 14-3-3 proteins and preventing its translocation to the nucleus, thus preventing inhibition of G1 progression. RPS6KA1 phosphorylates EPHA2 at 'Ser-897', highlighting the role of the RPS6KA-EPHA2 signaling pathway in controlling cell migration.
Gene References Into Functions
- FASN-induced S6 kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in diffuse large B-cell lymphoma. PMID: 29483509
- Polymorphism in p90Rsk gene is associated with Fetal Alcohol Spectrum Disorders. PMID: 29109170
- The results suggested a possible link between tRNALeu overexpression and RSK1/MSK2 activation and ErbB2/ErbB3 signaling, especially in breast cancer. PMID: 28816616
- Phosphorylation at Ser732 affects ribosomal S6 kinase 1 (RSK1) C-terminal tail (CTT) binding. PMID: 29083550
- RSK1 induced self-ubiquitination and destabilisation of UBE2R1 by phosphorylation but did not phosphorylate FBXO15. PMID: 27786305
- Genetic or pharmacologic inhibition of p90RSK in ganetespib-resistant cells restored sensitivity to ganetespib, whereas p90RSK overexpression induced ganetespib resistance in naive cells, validating p90RSK as a mediator of resistance and a novel therapeutic target PMID: 28167505
- These results suggest that RSK1 protects P-gp against ubiquitination by reducing UBE2R1 stability. PMID: 27786305
- Data suggest that UBR5 down-regulates levels of TRAF3, a key component of Toll-like receptor signaling, via the miRNA pathway; p90RSK is an upstream regulator of UBR5; p90RSK phosphorylates UBR5 as required for translational repression of TRAF3 mRNA. (UBR5 = ubiquitin protein ligase E3 component n-recognin 5 protein; TRAF3 = TNF receptor-associated factor 3; p90RSK = 90 kDa ribosomal protein S6 kinase) PMID: 28559278
- Data indicate that BTG2, MAP3K11, RPS6KA1 and PRDM1 as putative targets of microRNA miR-125b. PMID: 27613090
- The p90RSK has an essential role in promoting tumor growth and proliferation in non-small cell lung cancer (NSCLC). BID may serve as an alternative cancer treatment in NSCLC. PMID: 27236820
- RSK1 binds to EBP50 at its first PDZ domain, and mitogen activated RSK1 phosphorylates EBP50 at T156, an event that is crucial for its nuclear localization PMID: 26862730
- Data show that the 90 kDa ribosomal protein S6 kinases RSK1 and RSK2 play a key role in the homing of ovarian cancer cells in metastatic sites by regulating cell adhesion and invasion. PMID: 26625210
- RSK1 and 3 but not RSK2 are down-regulated in breast tumour and are associated with disease progression. RSK may be a key component in the progression and metastasis of breast cancer. PMID: 26977024
- PKD2 and RSK1 regulate integrin beta4 phosphorylation at threonine 1736 to stabilize keratinocyte cell adhesion and its hemidesmosomes. PMID: 26580203
- Results indicate that the phosphorylation of EphA2 at Ser-897 is controlled by RSK and the RSK-EphA2 axis might contribute to cell motility and promote tumour malignant progression. PMID: 26158630
- SL0101 and BI-D1870 induce distinct off-target effects in mTORC1-p70S6K signaling, and thus, the functions previously ascribed to RSK1/2 based on these inhibitors should be reassessed. PMID: 25889895
- RSK1 was constitutively phosphorylated at Ser-380 in nodular but not superficial spreading melanoma and did not directly correlate with BRAF or MEK activation. RSK1 orchestrated a program of gene expression that promoted cell motility and invasion. PMID: 25579842
- p90RSK-mediated SENP2-T368 phosphorylation is a master switch in disturbed-flow-induced signaling. PMID: 25689261
- These results suggest a critical role for ORF45-mediated p90 Ribosomal S6 Kinase activation in Kaposi's sarcoma-associated herpesvirus lytic replication. PMID: 25320298
- Data suggest that the ribosomal S6 kinase : protein kinase B (AKT) phosphorylation ratio could be useful as a biomarker of target inhibition by RAD001. PMID: 24332215
- RSK1 is specifically required for cleavage furrow formation and ingression during cytokinesis. PMID: 24269382
- RSK-mediated phosphorylation is required for KIBRA binding to RSK1. PMID: 24269383
- Data indicate that the S100B-p90 ribosomal S6 kinase (RSK) complex was found to be Ca2+-dependent, block phosphorylation of RSK at Thr-573, and sequester RSK to the cytosol. PMID: 24627490
- RSK1 is a novel regulator of insulin signaling and glucose metabolism and a potential mediator of insulin resistance, notably through the negative phosphorylation of IRS-1 on Ser-1101. PMID: 24036112
- Resistance to trastuzumab was observed in tumor cells with elevated MNK1 expression, furthermore, inhibition of RSK1 restored sensitivity to resistant cells. PMID: 22249268
- Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. PMID: 22674792
- results suggest p90 RSK facilitates nuclear Chk1 accumulation through Chk1-Ser-280 phosphorylation and that this pathway plays an important role in the preparation for monitoring genetic stability during cell proliferation. PMID: 22357623
- structure indicates that activation of RSK1 involves the removal of alpha-helix from the substrate-binding groove induced by ERK1/2 phosphorylation PMID: 22683790
- Data indicate that Plk1 siRNA interference and overexpression increased phosphorylation of RSK1, suggesting that Plk1 inhibits RSK1. PMID: 22427657
- melatonin enhances cisplatin-induced apoptosis via the inactivation of ERK/p90RSK/HSP27 cascade PMID: 22050627
- Collectively, these results identify a novel locus of apoptosomal regulation wherein MAPK signalling promotes Rsk-catalysed Apaf-1 phosphorylation and consequent binding of 14-3-3varepsilon, resulting in decreased cellular responsiveness to cytochrome c. PMID: 22246185
- Type I keratin 17 protein is phosphorylated on serine 44 by p90 ribosomal protein S6 kinase 1 (RSK1) in a growth- and stress-dependent fashion PMID: 22006917
- the results highlight a novel role for RSK1/2 and HSP27 phosphoproteins in P. aeruginosa-dependent induction of transcription of the IL-8 gene in human bronchial epithelial cells. PMID: 22031759
- Data show that VASP and Mena interact with RSK1. PMID: 21423205
- Data show that SH3P2 was phosphorylated on Ser(202) by ribosomal S6 kinase (RSK) in an ERK pathway-dependent manner, and such phosphorylation inhibited the ability of SH3P2 to suppress cell motility. PMID: 21501342
- our data provide evidence for a critical role for the activated RSK1 in IFNlambda signaling PMID: 21075852
- Data show that genetic variation in RPS6KA1, RPS6KA2, and PRS6KB2 were associated with risk of developing colon cancer while only genetic variation in RPS6KA2 was associated with altering risk of rectal cancer. PMID: 21035469
- small molecules such as celecoxib induce DR5 expression through activating ERK/RSK signaling and subsequent Elk1 activation and ATF4-dependent CHOP induction PMID: 21044953
- p22(phox)-based Nox oxidases maintain HIF-2alpha protein expression through inactivation of tuberin and downstream activation of ribosomal protein S6 kinase 1/4E-BP1 pathway PMID: 20304964
- was found to be activated by lead in a PKC- and MAPK-dependent manner PMID: 11861786
- Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. PMID: 11914378
- TF cytoplasmic domain-independent stimulation of protein synthesis via activation of S6 kinase contributes to FVIIa effects in pathophysiology. PMID: 12019261
- activated transiently by stromal cell-derived factor 1 alpha alone or synergistically in combination with other cytokines PMID: 12036856
- Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E PMID: 12080086
- RSK1 is negatively regulated by 14-3-3beta PMID: 12618428
- overexpressed in breast tumors PMID: 15112576
- Results suggest that active fibroblast growth factor receptor 1 kinase regulates the functions of nuclear 90-kDa ribosomal S6 kinase. PMID: 15117958
- that p90 ribosomal S 6 protein kinase 1 (RSK1) mediates the PGE2-induced phosphorylation of cAMP-response element binding protein PMID: 15615708
- monitored 14 previously uncharacterized and six known phosphorylation events after phorbol ester stimulation in the ERK/p90 ribosomal S6 kinase-signaling targets, TSC1 and TSC2, and a protein kinase C-dependent pathway to TSC2 phosphorylation PMID: 15647351
- S6 kinase 1 is a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase PMID: 15905173
Database Links
Protein Families
Protein kinase superfamily, AGC Ser/Thr protein kinase family, S6 kinase subfamily
Subcellular Location
Nucleus. Cytoplasm.
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
